1. Home
  2. HALO vs JAZZ Comparison

HALO vs JAZZ Comparison

Compare HALO & JAZZ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Halozyme Therapeutics Inc.

HALO

Halozyme Therapeutics Inc.

N/A

Current Price

$100.98

Market Cap

14.8B

Sector

Health Care

ML Signal

N/A

Logo Jazz Pharmaceuticals plc (Ireland)

JAZZ

Jazz Pharmaceuticals plc (Ireland)

N/A

Current Price

$243.34

Market Cap

16.1B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
HALO
JAZZ
Founded
1998
2003
Country
United States
Ireland
Employees
N/A
N/A
Industry
Biotechnology: Biological Products (No Diagnostic Substances)
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
14.8B
16.1B
IPO Year
2001
2007

Fundamental Metrics

Financial Performance
Metric
HALO
JAZZ
Price
$100.98
$243.34
Analyst Decision
Buy
Buy
Analyst Count
9
22
Target Price
$119.89
★ $296.77
AVG Volume (30 Days)
★ 2.3M
765.1K
Earning Date
11-05-2026
11-02-2026
Dividend Yield
N/A
N/A
EPS Growth
★ N/A
N/A
EPS
★ 5.12
0.04
Revenue
$151,862,000.00
★ $1,618,693,000.00
Revenue This Year
$35.97
$12.57
Revenue Next Year
$14.85
$5.14
P/E Ratio
★ $19.84
$6,224.00
Revenue Growth
N/A
N/A
52 Week Low
$61.23
$139.27
52 Week High
$134.00
$266.38

Technical Indicators

Market Signals
Indicator
HALO
JAZZ
Relative Strength Index (RSI) 27.51 63.09
Support Level $64.08 $236.70
Resistance Level $111.15 $250.49
Average True Range (ATR) 4.64 7.64
MACD -3.78 4.41
Stochastic Oscillator 6.04 86.68

Price Performance

Historical Comparison
HALO
JAZZ

About HALO Halozyme Therapeutics Inc.

Halozyme Therapeutics Inc is a biotechnology company focused on developing and commercializing novel oncology therapies. The company seeks to create therapies focused on human enzymes that alter tumors. Halozyme focuses on developing its proprietary products in therapeutic areas with a focus on oncology, and licensing its technology to biopharmaceutical companies to collaboratively develop products. ENHANZE drug delivery technology was introduced with the proprietary enzyme rHuPH20, to facilitate the subcutaneous delivery of injected drugs and fluids, with the goal of improving the patient experience with rapid SC delivery and reduced treatment burden. The company's operations are based in the United States, with minimal long-lived assets located internationally.

About JAZZ Jazz Pharmaceuticals plc (Ireland)

Jazz Pharmaceuticals is an Ireland-domiciled biopharmaceutical firm focused primarily on treatments for sleeping disorders and oncology. Jazz has nine approved drugs across neuroscience and oncology indications; its portfolio includes Xyrem and Xywav for narcolepsy, Zepzelca for the treatment of metastatic small cell lung cancer, Rylaze for acute lymphoblastic leukemia, and Vyxeos for acute myeloid leukemia. In May 2021, Jazz acquired GW Pharmaceuticals and gained its leading product, Epidiolex for the treatment of severe, rare forms of epilepsy.

Share on Social Networks: